|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Switzerland (N=200)** | 56.1 (12.2) | 74.5 | 13.2 (9.7) | 1.4 (1.0) | 1.2 (0.9) | 100 | 80.4 | 4.5 (1.3) | 1.3 (0.7) | 62.8 | 81 |
| **Sweden (N=247)** | 61.6 (13.1) | 80.4 | 15.6 (12.4) | NA | 1.3 (1.2) | 89.7 | 76.9 | 5.7 (1.3) | 1.5 (0.6) | 69.2 | 71.0 |
| **Spain (N=83)** | 58 (13.8) | 79.5 | 12.2 (7.5) | NA | NA | 92.8 | NA | 5.8 (1.5) | NA | 80.7 | 85.5 |
| **Slovenia (N=37)** | 54.6 (9.0) | 89.2 | 11.9 (6.9) | 4.2 (1.4) | 1.3 (0.6) | 89.2 | 87.0 | 6.2 (0.9) | NA\*\* | 64.9 | 100 |
| **Russia (N=607)** | 47.1 (12.0) | 86.5 | 9.8 (7.0) | 2.4 (1.3) | 0.3 (0.5) | 86.9 | 84.4 | 6.4 (1.0) | NA\*\* | 56.3 | 78.3 |
| **Norway (N=141)** | 53.7 (12.4) | 79.3 | 12.5 (8.5) | 3.1 (1.6) | 1.9 (1.1) | 80.7 | 76.3 | 5.6 (1.5) | NA\*\* | 72.3 | 75.9 |
| **The Netherlands (N=154)** | 57.9 (11.5) | 68.0 | 12.4 (8.0) | 4.0 (1.7) | 1.9 (0.8) | 80.5 | NA | 5.4 (1.2) | NA\*\* | NA | 32.1 |
| **Finland (N=120)** | 57.7 (12.3) | 77.5 | 17.4 (10.5) | NA | 1.7 (1.2) | 89.1 | 94.4 | 5.1 (1.5) | 1.4 (0.7) | 83.5 | 88.0 |
| **Denmark (N=260)** | 56.9 (12.5) | 76.9 | 11.7 (8.8) | 3.2 (1.9) | 1.8 (1.4) | 81.9 | 66.7 | 5.2 (1.4)\* | 1.5 (0.7) | 49.6 | 74.6 |
| **The Czech Republic (N=170)** | 51.6 (12.8) | 82.4 | 11.7 (6.6) | 2.8 (1.5) | 1.1 (0.8) | 62.6 | 68.4 | 6.5 (1.0) | 1.7 (0.6) | 40.7 | 81.2 |
| **Baseline characteristics of all patients (N=2019)** | **Age (years)** | **Gender (% female)** | **Disease duration (years)** | **N prior DMARDs** | **N prior biologics** | **RF (% positive)** | **anti-CCP (% positive)** | **DAS28** | **HAQ** | **Concomitant corticosteroids (%)** | **Concomitant DMARDs (%)** |

**Online Supplementary Table S1.** Baseline characteristics for each registry separately. \* DAS28 CRP \*\*MHAQ was not included in the analysis.